CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients Lose
As you and your readers may now be aware, the 340B Drug Pricing Program has been under siege for the past couple months. The program requires drug manufacturers to provide outpatient drugs to eligible health care organizations at significantly reduced prices, so that those savings can be passed on to the patients and the community…